September 2, 2021
NanoCarrier said on September 1 that its investigational otitis media drug ENT103, an antibiotic ear drops jointly developed with Tokyo-based otorhinolaryngology company Ceolia Pharma, met its primary endpoint in a Japanese PIII clinical study. In the study, the agent significantly...read more